Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 19 January 2018, 13:23 HKT/SGT
Share:
    

Source: Eisai
Eisai Enters into Licensing Agreement with Adlai Nortye for Potential Anticancer Agent E7046
(Prostaglandin E2 Receptor Type 4 Antagonist)

TOKYO, Jan 19, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a licensing agreement granting exclusive rights concerning the research, development, manufacture and marketing of Eisai's in-house discovered potential anticancer agent E7046, which is an investigational prostaglandin E2 (PGE2) type EP4 receptor antagonist, to Adlai Nortye Biopharma Co., Ltd. in all regions outside of Japan and part of Asia (excluding China).

E7046 is an orally administered, selective EP4 receptor antagonist discovered by Eisai's U.S. Andover research facility. It is suggested that PGE2 signals through EP4 receptors may suppress the antitumor activity of immune cells. By inhibiting EP4, E7046 is expected to act on the tumor microenvironment via a different mechanism to immune checkpoint inhibitors to potentially demonstrate antitumor effects.

Currently, E7046 is being investigated as a monotherapy in a Phase I clinical study as well as a Phase Ib clinical study in combination with radiotherapy/chemoradiotherapy.

Under this agreement, Eisai will receive from Adlai Nortye a one-time payment, milestone payments in accordance with the progress of development, as well as certain royalties according to sales revenue after launch.

Adlai Nortye is a science-led clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing new and effective immunotherapy for patients with cancer. Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. By licensing E7046 to Adlai Nortye, which is developing several tumor immunotherapies that have synergies with E7046, Eisai aims to maximize the value of the agent in order to hopefully contribute to the treatment of patients in the future who need tumor immunotherapies as soon as possible.

About E7046

Discovered in-house by Eisai, E7046 is an investigational, orally-administered EP4 antagonist that is believed to selectively bind to EP4 receptors, which are a subtype of prostaglandin E2 (PGE2) receptors. It is known that activating EP4 receptors causes monocytes, a type of white blood cell, to differentiate into M2 macrophages which have immuno-suppressive effects. As demonstrated in preclinical studies, inhibiting EP4 receptors reduces M2 macrophages, and by increasing M1 macrophages which activate immune response, antitumor effects can be expected. Currently E7046 is being investigated in a Phase I clinical study, and a Phase Ib clinical study of E7046 in combination with radiotherapy/chemoradiotherapy is also underway.

About Adlai Nortye Biopharma Co., Ltd.

Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs. Adlai Nortye focuses on discovering and developing important new treatments for cancer and metabolic diseases. Adlai Nortye's mission is to improve patient lives by identifying and acquiring differentiated innovative medicines that help people live better, live longer.
Adlai Nortye has 19 patents granted and 7 PCT published. With extensive experience in peptide and protein drugs, Adlai Nortye has expanded its expertise into small molecules and therapeutic antibodies. Through close collaborations with global partners, Adlai Nortye has successfully positioned ourselves in the fields of immuno-oncology and metabolic diseases and have several programs ongoing from early pre-clinical to Phase 3 ready.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Jan 19, 2018 13:23 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Mar 22, 2019 10:37 HKT/SGT
Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease
Mar 22, 2019 10:23 HKT/SGT
Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases
Mar 21, 2019 23:25 HKT/SGT
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease
Mar 12, 2019 07:43 HKT/SGT
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
Mar 7, 2019 11:30 HKT/SGT
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan
Feb 27, 2019 10:52 HKT/SGT
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan
Feb 21, 2019 13:50 HKT/SGT
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
Feb 13, 2019 08:29 HKT/SGT
Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy
Feb 4, 2019 11:57 HKT/SGT
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study
Jan 30, 2019 15:22 HKT/SGT
Eisai's Supplementary New Drug Application Submitted In Japan for Fycompa
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: